The preliminary efficacy and tolerability observed with vusolimogene oderparepvec (RP1) plus nivolumab (Opdivo) in patients with cutaneous melanoma signal the expansion of the use of oncolytic viruses to manage cancers that are resistant to PD-1 inhibition, according to Bartosz Chmielowski, MD.
Clinical Trials
AI-Driven Tool for Melanoma Diagnosis Displays Promising Results
A positive diagnostic performance was seen with the Dermaslayer device which is used as a decision support system for assessing potential melanoma. Findings included 95% sensitivity and 86% specificity in the first prospective study of its kind conducted in primary care settings, according to AI Medical Technology (NCT05172232).
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma
SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ — ImmVira’s first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. and China as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 months among melanoma patients who had failed previous immune-oncology treatment.
Cancer Vaccine: Moderna and Merck’s Melanoma vaccine moves on to third trial phase
Cancer Vaccine: Moderna and Merck recently announced promising results on a MRNA vaccine used to treat melanoma.